<DOC>
	<DOCNO>NCT01693133</DOCNO>
	<brief_summary>The objective study evaluate percentage patient complete diabetic foot ulcer ( DFU ) closure follow 12 week treatment either dehydrate human amnion/chorion membrane ( dHACM ) plus standard care ( SOC ) SOC alone .</brief_summary>
	<brief_title>Trial Dehydrated Human Amnion/Chorion Membrane ( dHACM ) In Management Diabetic Foot Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>1 . Male female age 18 old . 2 . The patient willing able provide inform consent participate procedure follow evaluation necessary complete study . 3 . Patient 's ulcer must diabetic origin size range 1 25 cm2 . Debridement do prior randomization , clinically indicate . 4 . Wounds diabetic foot ulcer locate dorsal plantar surface foot . 5 . Patients Type 1 2 diabetes ( criterion diagnosis diabetes mellitus per ADA ) . 6 . Ulcer must present minimum 30 day enrollment/randomization , documented failure prior treatment heal wound ( ≤25 % wound area reduction 14 consecutive day therapy immediately prior randomization treat standard protocol care ) . 7 . Affected leg offload ( removable walker total contact cast ) &gt; 14 consecutive day prior randomization . 8 . Serum Creatinine le 3.0mg/dl ( within last 6 month ) . 9 . HbA1c le 12 % within previous 60 day . 10 . Patient adequate circulation affect extremity , demonstrate one follow within past 60 day : Dorsum transcutaneous oxygen test ( TcPO2 ) result ≥30mmHg , OR ABIs result ≥0.7 ≤1.2 , OR Doppler arterial waveform , triphasic biphasic ankle affect foot . 11 . Females childbearing potential must willing use acceptable method contraception ( birth control pill , barrier , abstinence ) . 1 . Patients present ulcer probe bone ( UT Grade IIIAD ) . A positive probetobone confirm bone joint felt sterile , ophthalmological probe . 2 . Patients multiple wound foot wound within 3 cm wound care . 3 . Patients consider reasonable metabolic control , confirm HbA1c 12 % great time within previous 60 day . 4 . Known history poor compliance medical treatment . 5 . Patients currently enrol study . Concurrent enrollment study prohibit . 6 . Patients treat investigational drug ( ) therapeutic device ( ) within 30 day . 7 . Patients currently receive radiation therapy chemotherapy . 8 . Known suspected local skin malignancy index diabetic ulcer . 9 . Patients diagnose autoimmune connective tissue disease . 10 . Nonrevascularizable surgical site . 11 . Active infection index site currently treat antibiotic 12 . Any pathology would limit blood supply compromise healing . 13 . Patients receive biomedical topical growth factor wound within previous 30 day . Study ulcer previously treat tissue engineer material ( e.g . Apligraf® Dermagraft® ) scaffold material ( e.g . Oasis , Matristem ) within last 30 day . 14 . Patients know pregnant , plan become pregnant , breast feeding . 15 . Known allergy Gentamicin sulfate Streptomycin sulfate . 16 . Active Charcot deformity major structural abnormality foot . 17 . Wounds great one year duration without intermittent closure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>